Biological Age and Longevity Diagnostics Market Projected to Reach $5.58 Billion by 2030
核心洞察
The biological age and longevity diagnostics market is forecast to reach $5.58 billion by 2030, driven by accelerating adoption of personalized medicine.
FDA approved 16 new personalized treatments for rare diseases (搜索) in 2023, up from six in 2022, according to the Personalized Medicine Coalition (搜索).
Thrive Global (搜索) launched the Elite Longevity Assessment in April 2026, a multi-omics platform generating AI-powered aging scores and healthspan forecasts.
The global biological age and longevity diagnostics market is projected to reach $5.58 billion by 2030, according to a new market report, as precision healthcare adoption accelerates and companies race to build integrated platforms for measuring and managing aging.
The expansion is being fueled in part by a sharp rise in personalized treatment approvals. According to the Personalized Medicine Coalition (搜索), the US Food and Drug Administration (搜索) approved 16 new personalized treatments for rare diseases (搜索) in 2023, compared with six in 2022. Approvals during 2023 also included seven cancer (搜索) drugs and three therapies addressing other diseases and conditions. That momentum is expected to increase demand for biological age testing and longevity diagnostics across both clinical and consumer healthcare settings.
Innovation Reshapes the Competitive Landscape
In April 2026, Thrive Global (搜索) launched the Elite Longevity Assessment, a multi-omics longevity platform that combines advanced biomarker panels, metabolic profiling and lifestyle data. AI-powered analytics generate individualized aging scores and healthspan forecasts, supporting the identification of accelerated aging and underlying health risks. The platform also provides personalized recommendations involving nutrition, supplementation and lifestyle optimization, shifting the focus of health assessments toward preventive care and long-term health management.
Consolidation Builds Vertically Integrated Platforms
Market consolidation is supporting the development of integrated longevity offerings. Also in April 2026, Infinite Epigenetics (搜索) acquired Tally Health (搜索) for an undisclosed amount. The transaction combines Infinite Epigenetics' epigenetic diagnostic capabilities with Tally Health's at-home biological age testing, personalized longevity recommendations and healthy aging services. The acquisition is intended to create a vertically integrated healthspan platform serving the expanding biological age and longevity diagnostics market.
Regional Dynamics and Test Categories
North America was the largest region in the biological age and longevity diagnostics market in 2025, while Asia-Pacific is expected to be the fastest-growing region during the forecast period. The market analysis covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa, with country-level data spanning Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy and Spain.
The report segments the market by test type into epigenetic age testing, telomere length testing, multi-omics diagnostics, proteomic aging tests, microbiome-based longevity diagnostics, cellular senescence biomarker tests and organ age assessment tests. Sample types covered include blood, saliva, urine, tissue, buccal swab and hair samples.
Applications span preventive healthcare, personalized medicine, chronic disease risk assessment, wellness and fitness monitoring, and anti-aging research. End users include hospitals and clinics, diagnostic laboratories, research institutes, longevity clinics, academic institutions, direct-to-consumer users, and pharmaceutical and biotechnology companies.
Subsegments within epigenetic age testing include DNA methylation testing, histone modification analysis, chromatin accessibility profiling, epigenetic clock assessment and age prediction biomarker testing. Telomere length testing subsegments include quantitative polymerase chain reaction testing, flow cytometry and fluorescence in situ hybridization, Southern blot analysis, single telomere length analysis and telomerase activity testing.
Multi-omics diagnostics subsegments comprise genomics, transcriptomics, proteomics, metabolomics and lipidomics analysis. Proteomic aging tests include plasma protein biomarker testing, inflammatory protein analysis, cytokine profiling, enzyme activity analysis and growth factor biomarker testing. Microbiome-based longevity diagnostics cover gut microbiome sequencing, microbial diversity analysis, functional microbiome profiling, stool biomarker testing and microbial metabolite analysis.
Cellular senescence biomarker tests include senescence-associated beta galactosidase testing, cellular stress marker analysis, cell cycle arrest biomarker testing, senescence secretory phenotype profiling and DNA damage response testing. Organ age assessment tests cover cardiovascular, brain, liver, kidney and lung age assessment.
The report provides five years of historic data and a ten-year forecast, alongside ratios of market size and growth to related markets, GDP proportions and expenditure per capita, with country and regional historic and forecast data, competitor market share and market segments.
Companies featured in the analysis include Altos Labs (搜索), Infinite Epigenetics (搜索), TruDiagnostic (搜索), Viome Life Sciences Inc. (搜索), Function Health (搜索), Elysium Health Inc. (搜索), InsideTracker Inc. (搜索), Segterra Inc. (搜索), Human Longevity Inc. (搜索), FOXO Technologies Inc. (搜索), GlycanAge Ltd. (搜索), Gero PTE. Ltd. (搜索), Decode Age Technologies Pvt. Ltd. (搜索), MyDNAge Inc. (搜索), Generation Lab (搜索), SiPhox Inc (搜索)., Neko Health (搜索), Circulate Health (搜索) and EpiMedTech Global (搜索).